Bosutinib

CAS:380843-75-4

molecular formula:C26H29Cl2N5O3

molecular weight:530.45

application:It is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.

description:Bosutinib (rINN/USAN; codenamed SKI-606, marketed under the trade name Bosulif) is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.Originally synthesized by Wyeth, it is being developed by Pfizer.

 

Some commercial stocks of bosutinib (from sources other than the Pfizer material used for clinical trials) have recently been found to have the incorrect chemical structure, calling the biological results obtained with them into doubt.

 

Bosutinib received US FDA approval on September 4, 2012 for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.